Literature DB >> 24366751

In vitro characterization of a sustained-release formulation for enfuvirtide.

Sam N Rothstein1, Kelly D Huber, Nicolas Sluis-Cremer, Steven R Little.   

Abstract

Although approved by the U.S. Food and Drug Administration, enfuvirtide is rarely used in combination antiretroviral therapies (cART) to treat HIV-1 infection, primarily because of its intense dosing schedule that requires twice-daily subcutaneous injection. Here, we describe the development of enfuvirtide-loaded, degradable poly(lactic-co-glycolic) acid microparticles that provide linear in vitro release of the drug over an 18-day period. This sustained-release formulation could make enfuvirtide more attractive for use in cART.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24366751      PMCID： PMC3957899          DOI： 10.1128/AAC.02440-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Authors:  Jacqueline D Reeves; Stephen A Gallo; Navid Ahmad; John L Miamidian; Phoebe E Harvey; Matthew Sharron; Stefan Pohlmann; Jeffrey N Sfakianos; Cynthia A Derdeyn; Robert Blumenthal; Eric Hunter; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

2.  An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients.

Authors:  Antonio D'Avolio; Mauro Sciandra; Daniel Gonzalez de Requena; Allende Ibañez; Stefano Bonora; Giovanni Di Perri
Journal:  Ther Drug Monit       Date:  2006-02       Impact factor: 3.681

3.  Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.

Authors:  Paolo Ingallinella; Elisabetta Bianchi; Neal A Ladwa; Ying-Jie Wang; Renee Hrin; Maria Veneziano; Fabio Bonelli; Thomas J Ketas; John P Moore; Michael D Miller; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

4.  A retrospective mathematical analysis of controlled release design and experimentation.

Authors:  Sam N Rothstein; Jennifer E Kay; Francisco J Schopfer; Bruce A Freeman; Steven R Little
Journal:  Mol Pharm       Date:  2012-10-10       Impact factor: 4.939

5.  A unified mathematical model for the prediction of controlled release from surface and bulk eroding polymer matrices.

Authors:  Sam N Rothstein; William J Federspiel; Steven R Little
Journal:  Biomaterials       Date:  2008-12-19       Impact factor: 12.479
  5 in total
  1 in total

1.  Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation.

Authors:  Ibrahim M Ibrahim; Aditya N Bade; Zhiyi Lin; Dhruvkumar Soni; Melinda Wojtkiewicz; Bhagya Laxmi Dyavar Shetty; Nagsen Gautam; JoEllyn M McMillan; Yazen Alnouti; Benson J Edagwa; Howard E Gendelman
Journal:  Int J Nanomedicine       Date:  2019-08-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.